Representatives of Fulgent Genetics to Participate in Upcoming Virtual Conferences

Rhea-AI Summary

Fulgent Genetics (NASDAQ: FLGT), a technology-driven genetic testing company, has announced participation in two upcoming investor conferences. The company will present at the Credit Suisse 30th Annual Healthcare Conference on November 10, 2021, at 4:20 p.m. ET, and at the Piper Jaffray 33rd Annual Healthcare Conference on December 1, 2021. Webcasts of these presentations will be accessible on the Fulgent Genetics Investor Relations website. The company specializes in genetic testing for oncology, infectious diseases, and reproductive health, emphasizing high accuracy and competitive turnaround times.

TEMPLE CITY, Calif.--(BUSINESS WIRE)-- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced that members of its management team are scheduled to virtually participate in the following investor conferences:

Credit Suisse 30th Annual Healthcare Conference
Wednesday, November 10, 2021
Live presentation at 4:20 p.m. Eastern Time (1:20 p.m. Pacific Time)

Piper Jaffray 33^rd Annual Healthcare Conference
Wednesday, December 1, 2021

Webcasts of the presentations will be available on the Investor Relations section of the Fulgent Genetics website at ir.fulgentgenetics.com.

About Fulgent Genetics

Fulgent Genetics is a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health. Fulgent’s proprietary technology platform has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high accuracy, and competitive turnaround times. Combining next generation sequencing (“NGS”) with its technology platform, the Company performs full-gene sequencing with deletion/duplication analysis in an array of panels that can be tailored to meet specific customer needs. A cornerstone of the Company’s business is its ability to provide expansive options and flexibility for all clients’ unique testing needs through a comprehensive technology offering including cloud computing, pipeline services, record management, web portal services, clinical workflow, sequencing as a service and automated lab services.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211109005721/en/

Investor Relations Contacts:

The Blueshirt Group

Nicole Borsje, 415-217-2633, nborsje@blueshirtgroup.com

Source: Fulgent Genetics, Inc.

FAQ

When is Fulgent Genetics participating in the Credit Suisse Healthcare Conference?

Fulgent Genetics will present at the Credit Suisse 30th Annual Healthcare Conference on November 10, 2021, at 4:20 p.m. Eastern Time.

What is the date of the Piper Jaffray Healthcare Conference for Fulgent Genetics?

Fulgent Genetics is scheduled to participate in the Piper Jaffray 33rd Annual Healthcare Conference on December 1, 2021.

Where can I find the webcasts of Fulgent Genetics' investor presentations?

Webcasts of Fulgent Genetics' presentations will be available on their Investor Relations website at ir.fulgentgenetics.com.

What does Fulgent Genetics focus on in their genetic testing services?

Fulgent Genetics focuses on genetic testing in oncology, infectious diseases, rare diseases, and reproductive health.

What technology does Fulgent Genetics use for genetic testing?

Fulgent Genetics utilizes next generation sequencing (NGS) along with a proprietary technology platform for genetic testing.